Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.9052W HIGH $16.92
Volume
117.14 K
Value Traded
33.88 K
Short % Float
4.28%
Days to Cover
1.0
+16.26%Week
-39.55%1 Month
-75.35%3 Month
-81.85%6 Month
-99.98%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.55 M
EPS (TTM)
-22.05
P/E Ratio
-
Ent. Value
-5.74 M
Total Shares
2.39 M
Float Shares
2.28 M
Insiders
4.59%
Institutions
2.66%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
DCOY Catalyst Timeline
Dated clinical, regulatory and corporate events for Decoy Therapeutics Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Decoy Therapeutics Inc.
21Total events
7Upcoming
2Tier-1 (high impact)
2026 to 2027Coverage
Upcoming catalysts 2
Event history 13
●Oral PresentationDCOY-CoVPresentation
CTO Dr. Michael Lipp presents initial DCOY-CoV PK dataset at Boulder Peptide Symposium
endemic human coronavirusessource ↗
▲Preclinical PoCDCOY-CoVPreclinical
Preclinical PK data show once-weekly intranasal dosing potential for DCOY-CoV
endemic human coronaviruses (OC43, 229E, NL63, HKU1, and SARS-CoV-2)source ↗
▼Equity OfferingCorporate
Private placement of new unregistered warrants to purchase up to 2,368,868 shares
▲Preclinical PoCPreclinical
First-generation de novo filovirus candidate achieves low-micromolar IC50 against wild-type Ebola Zaire
Ebola Zaire virussource ↗
▲Preclinical PoCPreclinical
First-generation de novo filovirus candidate achieved IC50 of 1.56 μM against wild-type Ebola Zaire
Ebola Zairesource ↗
▲Patent GrantedIP / Competition
US Patent No. 12,226,474 granted for antiviral peptide conjugates
▲Preclinical PoCPreclinical
Discovery of initial cross-viral activity of pan-coronavirus fusion inhibitors against wild-type Ebola Zaire and Lassa fever virus
pan-coronavirus / Ebola Zaire and Lassa fever virussource ↗
▲Program DiscontinuationCorporate
Opened exploratory program to design D-MAVs against filoviruses and arenaviruses
filoviruses (Ebola, Marburg) and arenavirusessource ↗
●Trial InitiationTrial
Opened exploratory program to design D-MAVs against filoviruses
filovirus infectionssource ↗
●Composition Patent FiledIP / Competition
New patent filing for IMP3ACT platform design methods
Past FDA Catalysts and PDUFA Decisions
How DCOY actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 76%
Micro Cap(rank 500 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SP-3164 Small moleculeNCT05979857 | Lymphoma, Non-Hodgkin's, Adult | Phase 1 | NOT YET_RECRUITING | 72 | Aug 15, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every DCOY program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| HANISH ARNOLD CDirector | Sell | -15 5,000 held | $0.64 | 12/30/2025 |
Hedge Fund 13F Activity
Hedge Funds invested in DCOY
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in DCOY for Q2 2026. | ||||
DCOY Institutional Ownership Trends
DCOY Short Interest
Shares sold short, counted twice a month.
4.28%
Short % of Float
of tradable shares sold short
97.6K
Shares Sold Short
-35.1% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
119.4K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How DCOY ranks across every disease it competes in
Competitive Position is a premium feature
See how DCOY ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialDCOY News
DCOY▼ -7.5%on this news· ran to -22% by day 3
Decoy Therapeutics to Present at The Small Cap Showcase
Decoy Therapeutics, Inc. (NASDAQ: DCOY) announced that CEO Rick Pierce will present at The Small Cap Showcase on October 1, 2026, in New York City. The company is focused on developing Designable Multi-Antivirals (D-MAVs™) that target various viruses. The event will feature a corporate overview and one-on-one investor meetings.
Read more →DCOY▼ -7.8%on this news· ran to -23% by day 3shared move
Decoy Therapeutics Reports Preclinical Data Supporting Once-Weekly Intranasal Dosing for DCOY-CoV Program
Decoy Therapeutics has reported promising preclinical data for its DCOY-CoV program, demonstrating that a single intranasal dose can maintain therapeutic drug levels for up to seven days. This innovative approach targets multiple endemic coronaviruses, potentially benefiting high-risk patients. The company plans to present these findings at the Boulder Peptide Symposium and aims to enter clinical trials in 2027.
Read more →DCOY▲ +24.2%on this news
Decoy Therapeutics, Inc. Issues Correction to Warrant Inducement Transaction Press Release
Decoy Therapeutics, Inc. issued a correction to its earlier press release regarding a warrant inducement transaction. The correction clarifies that the new warrants will be exercisable immediately upon issuance, rather than requiring stockholder approval. This update aims to provide accurate information to stakeholders while all other details remain unchanged.
Read more →DCOY▼ -27.7%on this newsshared move
Decoy Therapeutics, Inc. Announces a Warrant Inducement Transaction for $3.85 Million in Gross Proceeds Priced At-The-Market under Nasdaq Rules
Decoy Therapeutics, Inc. has announced a warrant inducement transaction with an institutional investor, allowing for the immediate exercise of existing warrants at a reduced price. This transaction is expected to generate approximately $3.85 million in gross proceeds, which will be used for working capital. Additionally, new warrants will be issued in connection with this transaction, further enhancing the company's financial position.
Read more →DCOY▲ +21.1%on this newsshared move
Decoy Therapeutics Exploring Pan-Filovirus Program via FDA Animal Rule Pathway and Non-Dilutive Funding
Decoy Therapeutics is advancing its pan-filovirus program through the FDA Animal Rule pathway, aiming for expedited approval. The company reported significant in vitro activity of its D-MAVs against Ebola Zaire and Marburg viruses. Additionally, Decoy is seeking non-dilutive funding to support its biodefense pipeline and aims for Priority Review Voucher eligibility upon approval.
Read more →DCOY▲ +5.6%on this news
Decoy Therapeutics Expands Intellectual Property Portfolio Covering Designable Multi-Antivirals and the IMP³ACT™ Platform
Decoy Therapeutics has expanded its intellectual property portfolio to include seven patent families and 19 pending applications across multiple jurisdictions. This expansion protects various antiviral peptide conjugates and the methods used to manufacture them, showcasing the progress of their IMP³ACT platform. The company aims to develop adaptable antiviral drugs targeting shared viral mechanisms.
Read more →DCOY▼ -25.8%on this news
Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Consequence Global Health Threats
Decoy Therapeutics has reported that its D-MAV candidate shows promising in vitro activity against the Ebola Zaire virus. This finding validates the company's D-MAV platform and has led to the initiation of a new program targeting filoviruses. The candidate also demonstrated effectiveness against Lassa fever virus, highlighting its potential in pandemic preparedness.
Read more →DCOY▲ +7.5%on this news
Decoy Therapeutics Stockholders Elect Patricia Gauthier to Board of Directors
Decoy Therapeutics has elected Patricia Gauthier to its Board of Directors during the 2026 Annual Meeting. Gauthier, who has extensive experience in the biopharma industry, will support the advancement of Decoy's Designable Multi-Antivirals (D-MAVs) programs. Her background in commercial operations is expected to help the company effectively deliver its innovative antiviral solutions to patients.
Read more →DCOY▲ +73.8%on this news
Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing
Decoy Therapeutics, Inc. has announced a private placement financing agreement expected to yield approximately $3.5 million in gross proceeds. The financing includes milestone-based warrants that could provide up to an additional $14 million, contingent on regulatory approvals for clinical trials. The company aims to use these funds to advance its lead antiviral asset into clinical trials.
Read more →DCOY▼ -5.4%on this news· ran to -17% by day 1
Decoy Therapeutics' CEO to Participate in hVIVO Capital Markets Day in London
Decoy Therapeutics' CEO, Rick Pierce, will participate in hVIVO's Capital Markets Day on June 11, 2026, in London. The event will focus on early clinical development and the role of human challenge trials in advancing therapeutics. Decoy is advancing its D-MAVs pipeline, targeting a clinical launch in 2027. The company aims to expedite antiviral development through strategic partnerships and innovative technology.
Read more →DCOY▼ -7.4%on this news· ran to -27% by day 3shared move
Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors
Decoy Therapeutics has nominated Patricia Gauthier for election to its Board of Directors. Gauthier, currently a senior executive at Moderna, brings significant experience in biomanufacturing and health partnerships. Her nomination will be voted on during the company's Annual Meeting on July 14, 2026. CEO Rick Pierce expressed confidence in her ability to advance Decoy's antiviral programs.
Read more →DCOY▼ -6.3%on this news· ran to -25% by day 3shared move
Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV™ Candidate into the Clinic
Decoy Therapeutics has partnered with hVIVO to advance its Designable Multi-Antiviral (D-MAV) candidates into Phase 1 and Phase 2a studies. This collaboration aims to leverage hVIVO's expertise in clinical development and regulatory strategy to support Decoy's innovative approach to treating multiple respiratory viruses with a single adaptable therapeutic. The partnership is expected to streamline the transition of D-MAV candidates into clinical trials.
Read more →DCOYDecoy Therapeutics Names Brad Pentelute, MIT Professor of Chemistry, as Chair of Scientific Advisory Board
Decoy Therapeutics has appointed Dr. Brad Pentelute as Chair of its Scientific Advisory Board. Dr. Pentelute, a co-founder and MIT professor, will guide the scientific direction of Decoy's innovative Designable Multi-Antivirals (D-MAVs) platform. His expertise in peptide synthesis is expected to advance Decoy's clinical development efforts.
Read more →DCOY▼ -8.2%on this news
Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Decoy Therapeutics has announced that it has regained compliance with Nasdaq's minimum bid price requirement as of March 31, 2026. The company is now compliant with all other listing requirements. However, it will be monitored for one year, and any future non-compliance could result in delisting.
Read more →DCOY▼ -11.3%on this news
Decoy Therapeutics Announces 1-for-12 Reverse Stock Split
Decoy Therapeutics Inc. has announced a 1-for-12 reverse stock split effective March 6, 2026, aimed at regaining compliance with Nasdaq's minimum bid price requirement. This decision follows a stockholder meeting where the reverse split ratio was approved by the board. After the split, the total number of outstanding shares will decrease significantly, yet this won't alter stockholder ownership percentages. The reverse split is also expected to align Decoy Therapeutics' stock with market expectations, though it reflects prior challenges with share pricing.
Read more →DCOY▲ +53.4%on this news
Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform
Decoy Therapeutics has announced a Global Access Commitment Agreement with the Gates Foundation to develop a scalable manufacturing platform for peptide-conjugate antivirals. This initiative aims to provide widespread access to therapeutics in low- and middle-income countries. The platform will enable rapid manufacturing and distribution of antiviral products, enhancing global health responses to viral outbreaks.
Read more →DCOYSalarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics Trading under DCOY to commence on January 8, 2026
Salarius Pharmaceuticals has announced a rebranding to Decoy Therapeutics, along with a new Nasdaq ticker symbol DCOY, effective January 8, 2026. This change signifies the company's commitment to advancing next-generation peptide-conjugate therapeutics. Decoy's proprietary platform, enhanced by AI, aims to expedite candidate selection and facilitate innovative treatment development for viral and oncology targets. The company also outlines a focused plan for 2026, emphasizing the progress of its lead antiviral program and the pursuit of strategic partnerships.
Read more →DCOYREPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Board of Directors and Shareholders of Decoy Therapeutics, Inc. Opinion on the Financial Statements We have audited the accompanying consolidated balance she
Decoy Therapeutics, Inc. has reported its consolidated financial statements for the years ending December 31, 2024, and 2023. The audit opinion indicates that while the financial statements are fairly presented, the company continues to incur net losses and has substantial doubts about its ability to sustain operations in the future. The total liabilities have grown significantly, and the accumulated deficit has risen to $23,829,323. These factors raise concerns for investors regarding the company's financial stability and prospects for revenue generation.
Read more →DCOYUNAUDITED PRO FORMA CONSOLIDATED COMBINED FINANCIAL INFORMATION The following unaudited pro forma consolidated combined financial information is provided to aid you in your analysis of the financial aspects of the Merger
Salarius and Decoy are undergoing a merger that involves stock-for-stock exchanges, with Decoy becoming a wholly-owned subsidiary of Salarius. The transaction requires minimum proceeds of $6.0 million from a financing offering to close. Financial adjustments will be made based on an exchange ratio anticipating Decoy's value at $28.0 million and Salarius at $4.6 million. The merger is poised to be treated as a reverse asset acquisition, with Decoy identified as the accounting acquirer, although final determinations remain subject to change.
Read more →DCOYSalarius Pharmaceuticals, Inc. Announces $2.3 Million Registered Direct Offering
Salarius Pharmaceuticals, Inc. Announces $2.3 Million Registered Direct Offering HOUSTON, April 22, 2022 (GLOBE NEWSWIRE) - Salarius Pharmaceuticals, Inc. (NASDAQ SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment
Read more →About Decoy Therapeutics Inc.
Headquarters2450 HOLCOMBE BLVD, HOUSTON, TX, 77021
BIOPHARMAWATCH ELITE PLUS
Trade the next DCOY catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime